Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Third-quarter FDA submission is expected for use of implantable cardiac defibrillators in treating nonsustained but inducible ventricular tachycardia. Data from the Multicenter Unsustained Tachycardia Trial (MUSTT) will support the filing, the firm says. Preliminary results reported March 8 at the American College of Cardiology conference from the 2,200-patient trial sponsored by NIH show that among patients whose therapy was guided by electrophysiological testing, ICD patients had "risk of arrhythmic death reduced by greater than 50%" compared to the group receiving anti-arrhythmic drugs or other conventional therapy," according to a same-day Medtronic release
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT011472

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel